Objective To explore the changes in serum concentrations of angiogenic factors in patients with unstable angina pectoris.Methods A total of 60 patients with unstable angina pectoris was eligible for study and divided into diabetes group ( A group, n =20) and non-diabetes group (B group, n =40).Another 30 general-matched healthy subjects from medical examination center were enrolled as control group .Serum samples were collected , and serum concentrations of vascular endothelial growth factor (VEGF), angiopoietin-1, angiopoietin-2, angiogenin, angiostatin, basic fibroblast growth factor (bFGF), and platelet-derived growth factor-BB ( PDGF-BB) were measured by cytokine array technology and compared between the groups .Results Compared with the control group, the serum concentrations of VEGF [(325.2 ±210.1)pg/ml] and angiopoietin-2 [(3031.3 ±1865.5)pg/ml] were sig-nificantly increased in patients with unstable angina pectoris (both P <0.05).Whereas,no significant differences in serum concentra-tions of angiogenin,angiopoietin-1,angiostatin,bFGF,and PDGF-BB were detected between control group and patient groups .There were no significant differences in serum concentrations of above all 7 biomarkers between diabetes group and non-diabetes group .Con-clusions Serum concentrations of VEGF and angiopoietin-2 were increased in patients with unstable angina pectoris ,and diabetes didn't affect the increases in serum concentrations of VEGF and angiopoietin-2 caused by unstable angina pectoris .

To find out the risk factors of hospital infection in childhood primary nephrotic syndrome(nephrosis) and prophylactico therapeutic measures, 190 cases of child patients hospitalized for nephrosis during the period lasting from 1991 to 1999 were collected. Then a retrospective analysis of the distribution of the various risk factors was made using the single factor analysis and the logistic multi factor regression model. The hospital infection rate was found to be 34.2%, with respiratory infection accounting for 69.7%. The single factor analysis indicated that the risk factors included quantity of urinary protein per kilogram of weight within 24 hours(urinary protein), length of stay, length of hormone usage, entities of antibiotics used and length of such usage. The multi factor analysis indicated that the risk factors included urinary protein, entities of antibiotics used and length of such usage. The authors present the view that strengthening the control of respiratory diseases, setting up clean wards, and ensuring the rational use of antibiotics are some of the key measures for reducing the rate of hospital infection. The quantity of urinary protein is a sensitive index of hospital infection in nephrosis. Once diagnosis of nephrosis has been confirmed, it is necessary to use ACH in full dose and for a complete course of treatment so as to reduce the loss of protein from the urine as soon as possible.

Objective: To study the influence of occlusal force changes on apoptosis related gene Bcl-2 and Bax in rat periodontal ligament fibroblasts (PDLF). Furthermore, to explore the possible mechanism in remodeling of periodontal ligaments. Methods: Animal model of occlusal force changes was established by extracting the right first, second and third maxillary molars in male SD rats. Rats were sacrificed at 6,12 hours and 1, 2, 3, 5, 7, 14 and 28 days after teeth extraction(n=6), and their alveolar bone tissues were harvested. HE staining was used to observe the morphologic changes of alveolar bone tissues and immunohistochemistry were used to detect Bcl-2 and Bax expressions in PDLF. The rats of normal occlusal forces were used as control(n=6). The results were assigned a mean score based on the expressions and the intensity of cell positively stained for Bcl-2 and Bax. Results: Animal model of occlusal force changes was successfully established. HE staining showed that the control group had more pycnotic periodontal ligament, orderly aligned fibres, and flatter alveolar bone than model group. Immunohistochemical staining showed that expression of Bax reached its peak at 12 h after extracting the teeth(267.00?7.82), significantly higher than that of control group(25.67?4.97,P

05). Conclusion The maternal serum level of ADAM 12 in the first-trimester is a potential marker for aneupolyhaploid screening and early fetal loss prediction, and is suggested to be tested at 9-12 gestational weeks as part of prenatal screening.

AIM: To study inhibitory effect on proliferation of docetaxel on murine angiosarcoma cell line (ISOS-1) and compare with etoposide. METH ODS: In vitro, the inhibitory effect on proliferation of docetaxel and etoposide on ISOS-1 cells were carried out by Alamar Blue assay. In vivo study, after murine angiosarcoma model establishment, seventy mice were divided into trial and control group with 5 mice for each group. The dosages of docetaxel and etoposide were 5, 10, 20 mg · kg-1 respectively through administration by intravenous (iv) or intraperitoneal (ip) injection. The iv injection was performed once a week and total 4 times as one course. The ip injection was taken once a day, keeping for 5 d as a course and then repeated once more after 2 wk. The control group was injected with the normal saline. The volumes of the tumors and the survival days were calculated. RESULTS: In vitro study, the IC5o of docetaxel for ISOS-1 cells was 15.8 μg · L-1 showing obviously lower than that of et oposide group ( 1. 175 mg · L-1 ). In vivo study, the anti-tumor effect of docetaxel was better than that of et oposide at three different doses by iv, and all the in hibitory rates of tumor volume were more than 70 %. The life prolonging effect of 5 mg · kg- 1 docetaxel was similar to that of etoposide 10 mg · kg-1. The adverse reactions of ip injection were stronger than those of ivinjection. The dosage of etoposide 20 mg · kg-1 almost reached the lethal dose. CONCLUSION: Docetaxel shows obviously inhibitory effects on proliferation of murine angiosarcoma cell line (ISOS-1), which is superior to that of etoposide. It is safe and effective with low dosage once a week by iv.

Phytantriol (PT), ethanol (ET) and water were used to prepare in situ cubic liquid crystal (ISV2). The pseudo-ternary phase diagram of PT-ET-water was constructed and isotropic solution formulations were chosen for further optimization. The physicochemical properties of isotropic solution formulations were evaluated to optimize the composition of ISV2. In situ hexagonal liquid crystals (ISH2) were prepared based on the composition of ISV2 with the addition of vitamin E acetate (VitEA) and the amount of VitEA was optimized by in vitro release behavior. The phase structures of liquid crystalline gels formed by ISV2 and ISH2 in excess water were confirmed by crossed polarized light microscopy and small angle X-ray scattering, respectively. Rheological properties of ISV2 and ISH2 were studied by a DHR-2 rheometer. In vitro drug release studies were conducted by using a dialysis membrane diffusion method. Pharmacokinetics was investigated by determination of sinomenine hydrochloride (SMH) concentration in synovial membrane after intra-articular injection of SMH-loaded ISH2 in adjuvant-induced arthritis rats. The optimal ISV2 (PT/ET/water, 64 : 16 : 20, w/w/w) loaded with 6 mg x g(-1) of SMH showed a suitable pH, injectable and formed a cubic liquid crystalline gel in situ with minimum water absorption in the shortest time. The optimal ISV2 was able to sustain the drug release for 144 h. The optimal ISH2 system was prepared by addition of 5% VitEA into PT in the optimal ISV2 system. This ISH2 (PT/VitEA/ET/water, 60.8 : 3.2 : 16 : 20, w/w/w/w) was an injectable isotropic solution with suitable pH. The new ISH2 was able to sustain the drug release for more than 240 h. Local pharmacokinetics study indicated that the retention time and AUC(0-∞) of ISH2 group were increased significantly compared with that of SMH solution group and the AUC(0-∞) of ISH2 group was 6.01 times higher than that of SMH solution group. The developed ISH2 was suitable for intra-articular injection that may apply to patients in the treatment of rheumatoid arthritis.

Objective:To investigate the expressions of Smad2 and Smad4 in breast carcinoma tissue,and to analyze their relationships with oncogenesis and development of breast carcinoma and significances.Methods:Fifty-three samples of breast ductal carcinoma tissue and 50 samples of surrounding normal tissue were selected.The expression levels of Smad2 and Smad4 in cancer tissue and surrounding normal tissue were detected with immunohistochemical S-P method,and the relationships between the expression levels of Smad2 and Smad4 and the clinicopathologic parameters of breast carcinoma were evaluated.Results:The expression level of Smad2 protein in the breast carcinoma tissue was significantly higher than that in the surrounding normal tissue (z = - 2.08,P <0.05);the expression level of Smad4 protein in breast carcinoma tissue was lower than that in the surrounding normal tissue (z= - 5.01,P < 0.01).In breast carcinoma tissue,the Smad2 and Smad4 expressions were not significantly correlated with age (r=0.035,P >0.05;r=-0.077,P >0.05),tumor size (r= 0.128,P >0.05;r=0.133,P >0.05),lymph node invasion (r =0.163,P >0.05;r =0.006 P >0.05),distant metastasis (r =0.113,P >0.05;r = 0.126,P > 0.05),ER expression (r = 0.056,P > 0.05;r = 0.047,P > 0.05) and PR expression (r=0.129,P >0.05;r=0.107,P >0.05).However,the expression levels of Smad2 and Smad4 were negatively correlated with the expression of HER2 (r = - 0.388,P < 0.01;r = - 0.360,P < 0.01 ) and pathological grade (r = - 0.331,P < 0.05;r = - 0.388,P < 0.01 ).The expression of Smad2 was positively correlated to the expression of Smad4 in breast carcinoma (r=-0.83,P <0.01).Conclusion:The expressions of Smad2 and Smad4 may play an important role in the development of breast carcinoma,and they may be used as the potential biological markers for evaluating the degree of malignancy and prognosis of breast carcinoma.

Objective To investigate the therapeutic efficacy of transcatheter arterial embolization (TAE) in treating advanced bladder cancer. Methods A total of 22 patients with advanced bladder cancer were included in this study. The clinical data and the imaging materials were retrospectively analyzed. The clinical efficacy of TAE in treating advanced bladder cancer was evaluated. Results TAE was successfully accomplished in all the 22 patients. The preoperative and the postoperative abdominal pain scores were 4.73± 1.91 and 2.45±1.29 respectively, the difference was statistically significant (P<0.01); the preoperative and the postoperative ECOG scores were 3.14±0.47 and 2.68±0.56 respectively (P<0.05); the preoperative and the postoperative hemoglobin levels were (61.4±11.8) g/L and (79.3±14.5) g/L respectively (P<0.01). Of 7 patients with urinary tract obstruction, after the treatment the obstruction disappeared in 5 and was improved in 2, although the urination was still not smooth. All patients were followed up for (7.1±3.0) months. The 6-month survival rate was 54.5% (12/22). No serious complications occurred in all patients. Conclusion TAE can not only effectively improve the hematuria and urinary tract obstruction symptoms caused by bladder cancer, but also effectively control the tumor growth, improve the quality of life and prolong the survival time as well.